Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Weihai HEMO Jirui Biotechnology is an active Chinese medical device company specializing in innovative neurovascular interventional devices. Its flagship product, the Afentta™ intracranial thrombectomy aspiration catheter, is approved by China's NMPA and is used to treat ischemic strokes. The company collaborates with leading academic institutions and industry partners to develop new technologies targeting both ischemic and hemorrhagic strokes. Clinical data highlight improved procedure times, recanalization rates, safety profiles, and patient outcomes compared to existing options.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Weihai HEMO Jirui Biotechnology.